Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Teladoc Health Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Teladoc Health Inc trades at $5.79 (market cap $1.09B). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock and Teladoc Health Inc are close in size by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Teladoc Health Inc for 39 Days on average.
| MRVI | TDOC | |
|---|---|---|
Market Cap | $972.90M | $1.09B |
Volume | 4,325,710 | 4,279,268 |
Sector | Health | Health |
52-Week High | $9.00 | $9.72 |
52-Week Low | $2.83 | $4.47 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $1.08B | $1.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Teladoc Health (TDOC) trades at $5.81, down 1.86% on the day, with a bearish technical signal and mixed quarterly earnings performance. The company maintains strong gross margins at 68.97% but continues to report net losses, with a -7.13% net income margin for 2025. Recent developments include new executive appointments and ongoing legal investigations, while analyst consensus shows 35.71% buy ratings with a $8.83 price target.
TDOC presents a turnaround opportunity with attractive valuation metrics (P/S 0.43, EV/EBITDA 6.28) and positive cash flow from operations, but faces significant execution risks from persistent losses, BetterHelp segment challenges, and legal scrutiny. The stock trades near multi-year lows, offering potential upside if management can stabilize the business and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
